4.5 Article

Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis

期刊

OSTEOPOROSIS INTERNATIONAL
卷 32, 期 2, 页码 363-375

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00198-020-05601-y

关键词

Atypical femoral fracture; Beaking; Bisphosphonate; Femoral localized periosteal thickening; Glucocorticoid; Rheumatoid arthritis

资金

  1. Lilly Research Grant Program for Bone & Mineral Research

向作者/读者索取更多资源

The study found that the incidence of localized periosteal thickening in patients with rheumatoid arthritis was not high, but two patients developed incomplete atypical femoral fractures. Higher-dose prednisolone and higher-dose methotrexate were significant risk factors for LPT.
The incidence of localized periosteal thickening (LPT, also termed beaking) of the lateral cortex that often precedes an atypical femoral fracture (AFF) was not high in patients with rheumatoid arthritis (RA) but incomplete AFFs developed in two patients. Higher-dose prednisolone was a significant risk factor for LPT in patients with RA. Introduction Atypical femoral fractures (AFFs) are stress fractures; bisphosphonate (BP) use is a major risk factor for the development of such fractures. Localized periosteal thickening (LPT, also termed beaking) of the lateral cortex often precedes a complete or incomplete AFF. We evaluated the incidence of latent LPT in patients with rheumatoid arthritis (RA), to evaluate LPT progression, and to define LPT risk factors. Methods A total of 254 patients with RA were included; all underwent annual X-ray evaluation, dual-energy X-ray absorptiometry, and analyses of serum and bone metabolic markers for 2-3 years. LPT of the lateral cortex was sought in femoral X-rays. Results The incidence of LPT was 2.4% (6/254). Among patients on both BP and prednisolone (PSL) at enrollment, the incidence was 2.3% (3/131). Two femurs of two patients with LPT developed incomplete AFFs; LPT was extensive and associated with endosteal thickening. One patient had been on BP and PSL and microscopic polyangiitis was comorbidity. The other was on a selective estrogen receptor modulator and PSL. A daily PSL dose >5 mg (OR 11.4; 95%CI 2.15-60.2;p = 0.004) and higher-dose methotrexate (OR 1.22; 95%CI 1.01-1.49;p = 0.043) were significant risk factors for LPT. Conclusions The incidence of latent LPT was not high (2.4%) but incomplete AFFs developed in two RA patients. Higher-dose PSL because of a comorbid disease requiring glucocorticoid treatment other than RA or refractory RA were risk factors for LPT; X-ray screening for latent LPT would usefully prevent complete AFFs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据